key: cord-0975003-q7sinvvf
authors: Mazza, M.G.; Palladini, M.; Poletti, S.; Benedetti, F.
title: P.0086 Clinical and psychopathological predictors of fatigue in COVID-19 survivors: a machine learning study
date: 2021-12-30
journal: Eur Neuropsychopharmacol
DOI: 10.1016/j.euroneuro.2021.10.086
sha: 146816f98e118335a5c7b0aaf1be7ed37c2ca334
doc_id: 975003
cord_uid: q7sinvvf

Introduction: The COVID-19 pandemic has led to profound mental health consequences observed during acute infection and at short, medium, and long-term follow-up [1–3]. When considering long-term sequelae, a prevalent proportion of patients infected by SARS-CoV-2 experience a “Post-COVID-19 Syndrome” characterized by fatigue, depressive symptoms, sleep disturbances, and myalgia. In this context, fatigue is recognized as one of the leading complaints in COVID-19 survivors [4]. Long-term health consequences following COVID-19 and their impact on daily quality of life are largely unknown and need further investigation. Thus, questions about possible effects of mental health on fatigue, and of COVID-19 clinical severity on both, remained unanswered. We aim to predict long-term fatigue symptoms basing on clinical and psychopathological predictors through a machine learning approach. Methods: We evaluated the fatigue syndrome and the psychopathological status of 122 adult COVID-19 survivors (80 male, mean age 59.8±12.9) six months after hospital discharge for COVID-19. Clinical and psychopathological predictors were collected for the entire sample. Fatigue at six months was assessed using the Fatigue Severity Scale (FSS). Descriptive statistical analyses to compare means and frequencies were performed. To better disentangle the relationship between somatic and psychopathological predictors and the development of fatigue, we explored the effect of each predictor in affecting fatigue by implementing 5000 non-parametric bootstraps enhanced elastic net penalized logistic regression. The model's accuracy was estimated by 5-folds stratified nested cross-validations in the outer loop to define balance accuracy value (BA), class accuracies, and area under the receiver operator curve (AUC) (for a complete description of the method see [5]). Results: Six months after hospital discharge, 28%, 29%, and 24% of the total sample showed respectively depression (according to Zung Self-Rating Depression Scale), anxiety (according to State-Trait Anxiety Inventory form Y), and sleep disturbances (according to Women's Health Initiative Insomnia Rating Scale). Fatigue was present in 19% of the patients. When entering demographical, clinical, and psychopathological predictors in the elastic net penalized logistic regression, only depressive symptomatology significantly predicted the presence of fatigue at six months (Log Odds Ratio: 2.33;Standard deviation: 1.58;Lower and Upper 95% CI: -0.78 - 5.43;Variable Inclusion Probability: 96.7%). The 10-folds cross-validated elastic net model predicted fatigue with a BA of 65%, an AUC of 77%, and a specificity for the absence of fatigue of 74%, and a sensitivity for the presence of fatigue of 55%, showing good performances in excluding fatigue syndrome. Discussion: Besides confirming a high rate of long-term neuropsychiatric sequelae, our main finding is the strict association between fatigue and depression. We fear that, rather independent of pneumonia severity, major depression after COVID-19 is associated with persistent fatigue, thus worsening the burden of a non-communicable condition triggered by infection and by infection-related systemic inflammation, but then persisting on its own. Post-COVID syndrome, mainly characterized by fatigue, depression, and sleep disturbances, will affect COVID-19 survivors' daily functioning and place additional burden on the healthcare system. Clarifying the mechanisms and risk factors underlying such long-term symptomatology is essential to identify target population and to tailor specific treatment and rehabilitation interventions to foster recovery. No conflict of interest

The COVID-19 pandemic has led to profound mental health consequences observed during acute infection and at short, medium, and long-term follow-up [1] [2] [3] . When considering long-term sequelae, a prevalent proportion of patients infected by SARS-CoV-2 experience a "Post-COVID-19 Syndrome" characterized by fatigue, depressive symptoms, sleep disturbances, and myalgia. In this context, fatigue is recognized as one of the leading complaints in COVID-19 survivors [4] . Long-term health consequences following COVID-19 and their impact on daily quality of life are largely unknown and need further investigation. Thus, questions about possible effects of mental health on fatigue, and of COVID-19 clinical severity on both, remained unanswered. We aim to predict long-term fatigue symptoms basing on clinical and psychopathological predictors through a machine learning approach. Methods: We evaluated the fatigue syndrome and the psychopathological status of 122 adult COVID-19 survivors (80 male, mean age 59.8 ±12.9) six months after hospital discharge for COVID-19. Clinical and psychopathological predictors were collected for the entire sample. Fatigue at six months was assessed using the Fatigue Severity Scale (FSS). Descriptive statistical analyses to compare means and frequencies were performed. To better disentangle the relationship between somatic and psychopathological predictors and the development of fatigue, we explored the effect of each predictor in affecting fatigue by implementing 5000 non-parametric bootstraps enhanced elastic net penalized logistic regression. The model's accuracy was estimated by 5-folds stratified nested cross-validations in the outer loop to define balance accuracy value (BA), class accuracies, and area under the receiver operator curve (AUC) (for a complete description of the method see [5] ). Results: Six months after hospital discharge, 28%, 29%, and 24% of the total sample showed respectively depression (according to Zung Self-Rating Depression Scale), anxiety (according to State-Trait Anxiety Inventory form Y), and sleep disturbances (according to Women's Health Initiative Insomnia Rating Scale). Fatigue was present in 19% of the patients. When entering demographical, clinical, and psychopathological predictors in the elastic net penalized logistic regression, only depressive symptomatology significantly predicted the presence of fatigue at six months (Log Odds Ratio: 2.33; Standard deviation: 1.58; Lower and Upper 95% CI: -0.78 -5.43; Variable Inclusion Probability: 96.7%). The 10-folds cross-validated elastic net model predicted fatigue with a BA of 65%, an AUC of 77%, and a specificity for the absence of fatigue of 74%, and a sensitivity for the presence of fatigue of 55%, showing good performances in excluding fatigue syndrome. Discussion: Besides confirming a high rate of long-term neuropsychiatric sequelae, our main finding is the strict association between fatigue and depression. We fear that, rather independent of pneumonia severity, major depression after COVID-19 is associated with persistent fatigue, thus worsening the burden of a non-communicable condition triggered by infection and by infection-related systemic inflammation, but then persisting on its own. Post-COVID syndrome, mainly characterized by fatigue, depression, and sleep disturbances, will affect COVID-19 survivors' daily functioning and place additional burden on the healthcare system. Clarifying the mechanisms and risk factors underlying such longterm symptomatology is essential to identify target population and to tailor specific treatment and rehabilitation interventions to foster recovery. Introduction: Depressive disorder is a heterogenous condition that differs widely in both therapy response and prognosis. The ability to individually predict disease course early on is essential for optimal treatment planning. Here, we use a data-driven machine learning approach to test the potential of combining two sets of -omics data in addition to easyto-acquire clinical baseline variables for the prediction of two-year chronicity in major depressive disorder. Methods: Proteomics (243 analytes) and lipidomics (231 variables) assays were performed on whole blood serum at baseline in patients with baseline depression (n = 611 for proteomics, n = 790 for metabolomics, n = 608 for combined data) from the NESDA cohort 1 . Two classes of outcome (twoyear chronicity or remission) were balanced (49% vs 51%) and showed no significant differences in possible confounding factors (age, gender, bmi, years of education, antidepressant use at baseline, months of antidepressant use between baseline and follow-up). XGboost implementation in R was used with an 80-20 train-test split. An inner 10 times repeated 10-fold cross validation loop was used to optimize hyperparameters, mitigate overfitting issues and select for the best generalizable model (1000 hyperparameter-grid combinations were used) in the train set. Final models using a) clinical, psychological, and demographical data only (10 variables), b) added proteomics data and c) added lipidomics data were tested on an outheld test set and evaluated by their respective AUROC. Variable importance analysis was performed using SHAP 2 . Results: Using non-biological data only, our model was able to predict two-year chronicity (AUROC = 0.63, accuracy = 63%.) Addition of proteomics yielded substantially increased predictive performance (AUROC = 0.73, accuracy = 67%). Using lipidomics in combination with the non-biological data resulted in low predictive value (AU-ROC = 0.57, accuracy = 53%). Adding proteomics data to the lipidomics and non-biological data slightly increased model performance, but still showed poor performance (AU-ROC = 0.59, accuracy = 58%). In terms of absolute AUROC and balanced accuracy, the proteomics-only trained model showed optimal performance metrics (AUROC = 0.73, balanced accuracy = 70%). Variable importance analysis indicated that the most predictive proteomic analytes were stable for all proteomic-included models. For the model trained on both proteomic and non-biological data, symptom severity was the most important predictor, followed by proteomic analytes involved in coagulation and the immune system. Repeated analysis on proteomics data with a penalized logistic regression model (elastic net) showed lower performance and limited overlap of most important variables, indicating the importance of detection of non-linear patterns in the included biological data. Conclusion: Proteomics but not lipidomics data were able to augment the performance of clinical variables regarding depression chronicity 2 years later. Even though proteomics-informed predictions showed good performance (AUROC = 0.73), improvement in accuracy and feasibility of data-acquirement are needed to warrant clinical implementation. Introduction: Bipolar disorder (BD) represents one of the leading cause of disabilities worldwide [1] , calling for the identification of reliable markers of disease. To promote proper diagnosis and successful treatment, machine learning (ML) methods have been employed for individualized prediction based on candidate markers; however, their current performance is unclear [ 2 ; 3 ] . Understanding which ML algorithm is best suited for a given marker is crucial to build reliable predictive models. Here, we aimed to systematically review ML algorithms for predicting BD from biological, clinical and neuropsychological markers and compare their classification performances using a meta-analytic approach .

Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors

Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?

Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up

The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods

From local explanations to global understanding with explainable AI for trees